• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21342 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Addendum to Commission A22-108]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) - Addendum to Commission A22-114]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with preserved ejection fraction) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Spesolimab (generalized pustular psoriasis) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A21-130]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezepelumab (severe asthma) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for etranacogene dezaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Health Information and Quality Authority (HIQA) Health technology assessment of domiciliary invasive ventilation for adults with spinal cord injuries
2023     Health Information and Quality Authority (HIQA) International review of the epidemiology of long COVID
2023     Penn Medicine Center for Evidence-based Practice (CEP) Urine pregnancy screening for patients with and without the capacity for pregnancy
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Sponsoring of patient initiatives in Austria. 5th update of the systematic analyses 2014 to 2019]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: principles and criteria for gene selection for the molecular diagnosis of constitutional genetic diseases by next-generation sequencing - Report in support of the deployment of the sequencing service]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Update PET/PET-CT evidence for need based planning in the area of oncology]
2023     Austrian Institute for Health Technology Assessment (AIHTA) Perinatal and infant mental health care in Austria. A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol
2023     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines and clinical pathways for management of acute lower GI bleeding
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Stereotactic virtual navigation systems for percutaneous tumour ablation]
2023     NIHR Health Technology Assessment programme Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review
2023     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Thermidas thermal imaging system
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2023     NIHR Health Technology Assessment programme Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Trends in utilisation of ultrasound by older Australians (2010-2019)
2023     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023     NIHR Health and Social Care Delivery Program Mental health crisis care for children and young people aged 5 to 25 years: the CAMH-Crisis evidence synthesis
2023     Austrian Institute for Health Technology Assessment (AIHTA) Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patient/social, ethical and legal elements
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions - Part 2: Anorectal dysfunction, pelvic organ prolapse and perineal pain in women]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Extracorporeal shock wave therapy for orthopaedic indications]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [IV immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: osseointegration of bone-anchored prostheses in individuals living with lower limb amputation(s)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: NGAL assay for the detection of acute kidney injury]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: NK cell degranulation (natural killer)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: impact of physical activity on the adverse effects of cancer and cancer treatments in adults]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: analysis of personal and clinical characteristics associated with a favourable response to psychosocial interventions aimed at preventing and treating common mental disorders and symptoms]
2023     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Interventions to prevent and reduce gang-related crime among children and young adults
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [UAE and MRgFUS versus myoma enucleation - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Myomectomy versus no treatment - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Access routes of hysterectomy - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sutimlimab (haemolytic anaemia in adult patients with cold agglutinin disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (marginal zone lymphoma) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (glaucoma) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systemic therapy for children and adolescents as a psychotherapy method]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Maribavir (cytomegalovirus infection (treatment-refractory)) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (breast cancer, adjuvant) - Addendum to Commission A22-89]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olopatadine/mometasone (allergic rhinitis) - Benefit assessment according to §35a Social Code Book V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clopidogrel, prasugrel, and ticagrelor for the prevention of atherothrombotic events in acute coronary syndrome]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V]
2023     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2023     Scottish Health Technologies Group (SHTG) Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023     Scottish Health Technologies Group (SHTG) Store-and-forward teledermatology for triage of primary care referrals
2023     Scottish Health Technologies Group (SHTG) Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023     Scottish Health Technologies Group (SHTG) An assessment of the Feeling Good app
2023     Scottish Health Technologies Group (SHTG) Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023     Scottish Health Technologies Group (SHTG) Living donor transplantation
2023     Scottish Health Technologies Group (SHTG) Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023     Scottish Health Technologies Group (SHTG) Community based respiratory care services for patients with chronic respiratory conditions
2023     Scottish Health Technologies Group (SHTG) Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Syphilis - detection, diagnosis, optimal antibiotic use, and follow-up]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: the management of myalgic encephalomyelitis / chronic fatigue syndrome]
2023     NIHR Public Health Research (PHR) programme Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023     NIHR Public Health Research (PHR) programme A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023     NIHR Health Technology Assessment programme Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023     NIHR Health Technology Assessment programme Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of platelet-rich plasma for the treatment of knee osteoarthritis]
2023     Norwegian Institute of Public Health (NIPH) Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023     Belgian Health Care Knowledge Centre (KCE) Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023     The Federal Joint Committee (G-BA) Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2023     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) Assessment of hip protectors for users at risk of falls
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Early detection tools for emotional distress in adult people with cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023     NIHR Health Technology Assessment programme Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: cryotherapy for the prevention of taxane-induced peripheral neuropathy]
2023     Agency for Care Effectiveness (ACE) Echinocandins for treating invasive candidiasis
2023     Agency for Care Effectiveness (ACE) Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023     Agency for Care Effectiveness (ACE) Inhaled corticosteroids with long acting beta-2 agonists for treating asthma